Lipoprotein(a) and coronary heart disease: Meta-analysis of prospective studies

Circulation

Volumn 102, Issue 10, 2000, Pages 1082-1085

  Danesh, John ^a,b   Collins, Rory ^a   Peto, Richard ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b RADCLIFFE INFIRMARY   (United Kingdom)

Author keywords

Coronary disease; Lipoproteins; Meta analysis

Indexed keywords

LIPOPROTEIN A;

ARTICLE; CLINICAL TRIAL; FOLLOW UP; HEART INFARCTION; HUMAN; ISCHEMIC HEART DISEASE; LIPOPROTEIN BLOOD LEVEL; META ANALYSIS; MORTALITY; PRIORITY JOURNAL;

EID: 0034609562     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.102.10.1082     Document Type: Article

References (38)

1. Lipoprotein(a) in coronary heart disease: Is it a risk factor after all?
2. Has lipoprotein 'little' (a) shrunk?
3. Lipoprotein(a) as a risk factor for coronary artery disease
4. Lipoprotein(a) as a risk factor for ischemic heart disease: Meta-analysis of prospective studies
5. Predictive value of electro-phoretically detected lipoprotein(a) for coronary heart disease and cerebrovascular disease in a community-based cohort of 9936 men and women
6. A prospective study of lipoprotein(a) and the risk of myocardial infarction
7. Lipoprotein(a) levels and risk of coronary heart disease in men the lipid research clinics coronary primary prevention trial
8. Apolipoproteins and ischaemic heart disease: Implications for screening
9. Relation of serum homocysteine and lipoprotein(a) concentrations to atherosclerotic disease in a prospective Finnish population based study
10. A prospective investigation of elevated lipoprotein(a) detected by electrophoresis and cardiovascular disease in women: The Framingham heart study
11. A prospective case-control study of lipoprotein(a) levels and apo(a) size and risk of coronary heart disease in Stanford five-city project participants
12. Lipoprotein(a) and coronary heart disease risk: A nested case-control study of the Helsinki heart study participants
13. Elevated plasma lipoprotein(a) and coronary heart disease in men aged 55 years and younger a prospective study
14. Ten-year follow-up results from the Goettingen Risk, Incidence, and Prevalence Study (GRIPS), I: Risk factors for myocardial infarction in a cohort of 5790 men
15. Predictive value of apolipoproteins in a prospective survey of coronary artery disease in men
16. Is lipoprotein(a) an independent risk factor for ischemic heart disease in men? The Quebec cardiovascular study
17. Lipoprotein(a) and cholesterol levels act synergistically and apolipoprotein A-I is protective for the incidence of primary acute myocardial infarction in middle-aged males: An incident case-control study from Sweden
18. Apolipoprotein(a) isoforms and coronary heart disease in men: A nested case-control study
19. Hypertriglyceridemia and elevated lipoprotein(a) are risk factors for major coronary events in middle-aged men
20. Lipoprotein(a) and coronary heart disease a prospective case-control study in a general population sample of middle aged men
21. A prospective study of obesity, lipids, apolipoproteins and ischaemic heart disease in women
22. Lipoprotein(a) as a risk factor for atherosclerotic diseases
23. Lp(a) lipoprotein level predicts survival and major coronary events in the Scandinavian Simvastatin Survival Study
24. Lipoprotein(a) is an independent risk factor for cardiovascular disease in hemodialysis patients
25. Lipoprotein(a) as a risk factor for coronary artery disease in hemodialysis patients
26. Thrombogenic factors and recurrent coronary events
27. Lipoprotein(a) as a risk predictor for cardiac mortality in patients with acute coronary syndromes
28. Serum lipids, lipoprotein(a) and apo(a) isoforms in patients with established coronary artery disease and their relation to disease and prognosis after coronary by-pass surgery
29. Lack of association between lipoprotein(a) concentrations and coronary heart disease mortality in diabetes: The Wisconsin epidemiologic study of diabetic retinopathy
30. Serum Lp(a) lipoprotein concentration is not associated with clinical and angiographic outcome five years after coronary artery bypass graft surgery
31. Plasminogen activator inhibitor in plasma: Risk factor for recurrent myocardial infarction
32. Fibrinogen, C-reactive protein, albumin or white cell count meta-analyses of prospective studies of coronary heart disease
33. Underestimation of risk associations due to regression dilution in long-term follow-up of prospective studies
34. Lipoprotein(a) in stored plasma samples and the ravages of time: Why epidemiological studies might fail
35. Role of lipoprotein(a) and apolipoprotein(a) phenotype in atherogenesis: Prospective results from the Bruneck study
36. Lipoprotein(a) concentration and apolipoprotein(a) size: A synergistic role in advances atherosclerosis?
37. Association between apolipoprotein(a) phenotypes and coronary heart disease at a young age
38. Effects of lowering elevated LDL cholesterol on the cardiovascular risk of lipoprotein(a)